NetworkNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Names New Senior VP of Global Sales and Business Development
Green Hygienics (OTCQB: GRYN) has appointed a new senior vice president. David Racz, a seasoned pharmaceutical executive, has been named senior VP of global sales and business development for the innovative, tech-driven company. Racz has garnered extensive experience in the both the pharma and cannabis sectors, having served in global, senior-level positions with well-known pharmaceutical companies including Pfizer, GlaxoSmithKline and Novartis. At Pfizer, he was vice president of sales and human resources, overseeing the largest expansion in Pfizer’s sales force in history. At SmithKline Beecham, he managed more than 4,000 sales, marketing and R&D employees, who were located in 20 countries throughout Asia, Latin America, Australia, and South Africa. He was also a member of the team that coordinated and managed the transcontinental merger of SmithKline and Beecham. At Novartis, he supervised strategy and resource allocation for the $8 billion health-care company and managed 14,000 global employees. He entered the cannabis market in 2008 when he worked with legislative bodies in Colorado to develop the state’s medical cannabis laws, and starting in 2011, he led a team that applied for and acquired six cannabinoid-related patents, discovered two cannabis chemical structures, built a cannabis DNA library with more than 4,000 different strains and oversaw the early advancement of cannabis genetic engineering for application in large-scale production.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Green Hygienics (OTCQB: GRYN) has appointed a new senior vice president. David Racz, a seasoned pharmaceutical executive, has been named senior VP of global sales and business development for the innovative, tech-driven company. Racz has garnered extensive experience in the both the pharma and cannabis sectors, having served in global, senior-level positions with well-known pharmaceutical companies including Pfizer, GlaxoSmithKline and Novartis. At Pfizer, he was vice president of sales and human resources, overseeing the largest expansion in Pfizer’s sales force in history. At SmithKline Beecham, he managed more than 4,000 sales, marketing and R&D employees, who were located in 20 countries throughout Asia, Latin America, Australia, and South Africa. He was also a member of the team that coordinated and managed the transcontinental merger of SmithKline and Beecham. At Novartis, he supervised strategy and resource allocation for the $8 billion health-care company and managed 14,000 global employees. He entered the cannabis market in 2008 when he worked with legislative bodies in Colorado to develop the state’s medical cannabis laws, and starting in 2011, he led a team that applied for and acquired six cannabinoid-related patents, discovered two cannabis chemical structures, built a cannabis DNA library with more than 4,000 different strains and oversaw the early advancement of cannabis genetic engineering for application in large-scale production.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
